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Abstract
There are few animal models of cognitive decline that 
could be considered as prominent as the cholinergic le-
sion model of Alzheimer’s disease. Alzheimer’s disease 
is a neurodegenerative disorder associated with aging 
with accentuated progressive cognitive impairment. 
Its multiple complex sequential and interactive neural 
pathways may lead to the understanding that a single 
agent intervention might be insufficient to impact the 
course of this disease. The current pharmacological 
treatment is palliative and, although it may slow down 
the disease’s progression, it still cannot offer cure. The 
combination of drugs and antioxidant substances has 
been investigated, nevertheless there are few studies 
demonstrating optimal and consistent results based on 
this combination. Thus, the purpose of this paper is to 
highlight cell-based therapies as prospective treatment 
of peripheral and central nervous system disorders.
Keywords: Animal models of cognitive decline; Alzhei-
mer’s disease; stem cell based therapy.
Resumen
Existen pocos modelos animales de degeneración cogni-
tiva que podrían ser considerados tan importantes como 
el modelo de lesión colinérgica de la enfermedad de Al-
zheimer. La enfermedad de Alzheimer es una patología 
neurodegenerativa asociada con el envejecimiento y con 
degeneración cognitiva acentuada y progresiva. Sus 
complejas y múltiples vías neurales secuenciales pueden 
conducir a la comprensión de que las intervenciones de 
agente único pueden ser insuficiente para impactar el 
curso de esta enfermedad. El tratamiento farmacológico 
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actual es paliativo y, aunque pueda retardar el progreso 
de la enfermedad, no es capaz de ofrecer una cura. La 
combinación de drogas y sustancias antioxidantes han 
sido investigadas, sin embargo, existen pocos estudios 
que demuestran resultados consistentes basados en esta 
presunción. Así, el objetivo de este artículo fue desta-
car las terapias basadas en la reposición celular como 
potencial tratamiento para enfermedades del sistema 
nervioso periférico y central.
Palabras clave: modelos animales de degeneración 
cognitiva; enfermedad de Alzheimer; terapia de células 
troncales.
Resumo
Existem poucos modelos animais de declínio cognitivo 
que poderiam ser considerados tão importantes como o 
modelo de lesão colinérgica da doença de Alzheimer. A 
doença de Alzheimer é uma patologia neurodegenera-
tiva associada com o envelhecimento e com acentuada 
e progressiva disfunção cognitiva. Suas complexas e 
múltiplas vias neurais sequenciais e pode conduzir à 
compreensão de que as intervenções de agente único 
pode ser insuficiente para impactar o curso desta doença. 
O tratamento farmacológico atual é paliativo e, embora 
possa retardar a progressão da doença, não é capaz de 
oferecer a cura. A combinação de drogas e substâncias 
antioxidantes tem sido investigada, no entanto, existem 
poucos estudos que demonstram resultados consistentes 
baseados nesta presunção. Assim, o objetivo deste artigo 
foi destacar as terapias baseadas na reposição celular 
como potencial tratamento para doenças do sistema 
nervoso periférico e central.
Palavras-chave: modelos animais de declínio cognitivo; 
doença de Alzheimer; terapia de células tronco.
In acute cases of neurological damages such 
as stroke or spinal cord injury, different types of 
neurons and glial cells die within restricted areas 
of the central nervous system (CNS) area over a 
short period of time (Lindvall & Kokaia, 2010). In 
chronicle situations, there is either selective loss 
of a specific cell population such as dopaminergic 
neurons in Parkinson’s disease (PD) or a wide-
spread degeneration of many types of neurons over 
a period of several years such as in Alzheimer’s 
disease (AD) (Lindvall & Kokaia, 2010).
Alzheimer’s disease is the most prevalent neu-
rodegenerative disorder associated with aging (Nie-
dowicz, Nelson, & Murphy, 2011) and its incidence 
is expected to grow intensively such that by 2050 
more than 100 million people worldwide will have 
developed this dementia (Prince, Bryce, & Ferri, 
2011). AD is characterized by the progressive loss 
of cognitive functions, specially, memory. Howev-
er, besides compromising the memory, AD is also 
responsible for deficits in attention, orientation, or-
ganization, executive functions such as the capacity 
of planning and judging (Weintraub et al., 2009) 
leading to the inability of living independently.
Pathological hallmarks of AD are dystrophic 
neuritis associated with plaques and neurofibril-
lary tangles within nerve cell bodies in the basal 
forebrain and neocortical cholinergic pathways 
(Wszolek, 2008). The widespread loss of neu-
rons and synaptic connectivity in AD seem to 
be caused by the accumulation of toxic species 
of the β-Amyloid (Aβ) peptide (Chen & Blur-
ton-Jones, 2012).
It has been reported that the toxic deposit of 
Aβ causes membrane blebbing and cell shrinkage 
followed by DNA damage, generation of nuclear 
apoptotic bodies, DNA fragmentation, and other 
classic hallmarks of apoptosis (Paradis, Douil-
lard, Koutroumanis, Goodyer, & LeBlanc, 1996). 
Preventing the apoptosis induced by Aβ and re-
constructing the cholinergic circuitry could be 
an optimal treatment for AD. However, since the 
relationship among pathological features remains 
elusive, pharmacological therapies keeps the focus 
on the function of acetylcholine through cholin-
esterase inhibitors (ChE-I) while stem cells (SC) 
researchers look for a cell-based therapy (Oliveira 
& Hodges, 2005).
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Pharmacotherapy
Multiple complex sequential and interactive 
pathways are involved in the AD’s neurobiology, 
and interventions with a single agent could be 
insufficient to impact the disease’s course (Cum-
mings, Gould, & Zhong, 2012). Pharmacological 
treatment for AD is palliative, having the prop-
erty of slowing down the speed of the disease’s 
progression. Several studies have shown that the 
combination treatment of acetylcholinesterase in-
hibitor (AChE-I) and memantine prolongs the time 
an AD’s patient is able to live more independently 
(Pfeil, Kressig, Thomas, & Szucs, 2012). Howev-
er, according to Pfeil et al. (2012) these benefits 
can only be seen after a year of this combination 
therapy.
Cholinesterase inhibitors increase cholinergic 
synaptic transmission by holding back acetylcho-
linesterase in the synaptic cleft, thereby decreasing 
the hydrolysis of acetylcholine released from the 
presynaptic neurons (Chu, 2012). Despite the ex-
tensive discussion on the effectiveness of AChE-I 
donepezil, galantamine and rivastigmine, these 
are the drugs currently approved by the FDA for 
treating AD’s patients in moderate and mild stages 
(Mini Mental State Examination scores between 
10 and 24), showing a delay in the cognitive im-
pairment and some of the behavioral problems 
(Sadowsky & Galvin, 2012).
In general, AChE-I drugs are well tolerated; 
nevertheless, dose-related adverse effects may 
occur. It is not possible yet to identify which AD 
patient will respond best to each one of these drugs, 
nor predict who will develop more intense adverse 
reactions such as vomiting, nausea and diarrhea, the 
most prevalent ones (Sadowsky & Galvin, 2012). 
Meanwhile, studies of AD’s patients treated by 
rivastigmine, donepezil and galantamine for up to 
4 years demonstrated fewer declines in cognitive 
functions than expected (Chu, 2012).
Some studies have investigated the role of anti-
oxidant treatment in AD. Epicatechin, a polyphenol 
flavan-3-ol that can be found in food and beverages 
such as chocolate in natura, red wine, some fruit 
and teas, especially the traditional green tea Camel-
lia sinensis, can exert neuroprotective properties 
(Aktas, Waiczies, & Zipp, 2007). Fruit and vege-
tables rich in flavonoid played an important role 
in the prevention of motor and cognitive declines 
related to aging (Bickford, Shukitt-Hale, & Joseph, 
1999). In an in vitro experiment, epichatechin’s 
antioxidant property could be responsible for the 
prevention of cells deaths by reducing the oxida-
tive stress (Schroeter, Williams, Matin, Iversen, & 
Rice-Evans, 2000).
Limited data are available considering an-
tioxidant treatments in dementia. According to 
Weinmann, Roll, Schwarzbach, Vauth and Wil-
lich (2010), the extract of Ginkgo Biloba, an herb 
considered to have potent antioxidant property due 
to the presence of flavonoids and terpenoids, is 
not truly recommended for AD’s treatment. Even 
though in the subgroup of patients with AD there 
was a significant advantage of Ginkgo Biloba com-
pared to placebo in the conducted study, there was 
no relevant benefit of the herb in the treatment of 
neuropsychiatric symptoms. Therefore, addition-
al studies comparing the relative effectiveness of 
Gingko Biloba and AChE-I should be conducted 
(Weinmann et al., 2010).
Huperzine-A (Hup-A), an alkaloid isolated from 
Huperzia serrata, an herb used in the traditional 
Chinese medicine for treating fevers, swellings, 
hypertension and memory impairment is consid-
ered to be a potent AChE–I proven to effectively 
improve the learning, memory performance and 
behavioral dysfunction in Chinese with AD (Gao, 
Zheng, Yang, Tang, & Zhang, 2009; Wang, Yan, 
& Tang, 2006). In a study with rats, an isolation 
of brain mitochondria demonstrated the protective 
effects of Hup-A on mitochondrial function and on 
mitochondria’s extended noncholinergic functions 
as well, providing a significant potential for the 
design of anti-AD drugs (Gao et al., 2009).
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Animal Models for Alzheimer’s Disease
Animal models have been very important to 
understand the complex pathogenic mechanism 
underlying neurodegenerative diseases. The use 
of neurotoxins characterizes an alternative to re-
produce an AD model. The cytotoxin infusion of 
agents capable of destroying cell populations or 
brain structures is a common method for this (see 
table 1). Even though the neurotoxins’ actions 
destroy neuronal cells by a massive postsynaptic 
depolarization (Barker & Dunnett, 1999), they have 
their own specificities and limitations.
Transgenic models have also been developed, 
providing considerable information about the AD’s 
neuropathology. According to Granic, Masman, 
Luiten and Eisel (2010) transgenic models of AD 
rely on inherited forms of the disease and present 
indistinguishable clinical and histopathological 
features. It is important to highlight that, even 
though there is a great quantity of transgenic AD 
models, there is no perfect model that incorporates 
all aspects of AD and some effective results in the 
animals fail on clinical trials.
Neuropathway mechanical lesions in the elec-
trolytic model by direct target destruction or fim-
bria-fornix’ transaction by pathway axotomy can 
also be an option; nevertheless there are chances 
of unspecific results (Oliveira & Hodges, 2005).
In addition to the models presented, others can 
be pointed such as aging animals characterized by 
an overall age related deficits of neurotransmitter 
systems. This senescence model favors the natural 
decline of neurotransmitter systems, however it is 
not a widespread model due to its long time period 
keeping and maintaining the animals as well as the 
animals’ inconsistence cognitive decline (Oliveira 
& Hodges, 2005).
Stem Cells Therapy for 
Neurodegenerative Diseases
In the 80’s, researchers believed that neurode-
generative diseases such as AD and PD could bene-
fit from SCs once there would be an increase of the 
cells in the brain (Gash, Collier, & Sladeck, 1985). 
Almost 30 years later, stem cell-based therapies 
have aimed to replace missing or defective cells 
Table 1 
Animal models – Alzheimer’s disease
Model Mechanism Anatomic target References
Cytotoxin infusion
Quisqualic acid, Ibotenic 
acid, Kainic acid, AMPA
Glutamate overexci-
tation Basal forebrain
Waite, Chen, Wardlow, & Thal (1994); Dunnett, 
Whishaw, Jones, & Bunch, (1987); Waite & Thal 
(1996); Inglis & Semba (1997); Yamada & Nabeshi-
ma (2000).
Trangenics
Amyloid Precursor Pro-
tein (APP) Aβdeposition
Hippocampus, 
cortex, thalamus Yamada & Nabeshima (2000); Kulnane & Lamb 
(2001); Gordon et al. (2001); Pennanen, Welzl, 
D’Adamo, Nitsch, & Gotz (2004); Lee et al. (2012). Tau Protein 
Neurofibrillary 
tangles, filamentous 
tau aggregate
Amygdala, basal 
forebrain
Mechanical destruction
Fimbria-Fornix tran-
section Fimbria-Fornix
Yamada & Nabeshima (2000); Krugel, Bigl, Es-
chrich, & Bigl (2001); Vale-Martinez et al. (2002); 
Xuan, Luo, Ji, & Long (2009). Electrolytic NBM, amygdala
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in many disorders, but a lot is to be known about 
the mechanism of the SCs inside the organism. 
Shortly, SCs are classically defined as cells that 
have the ability to renew themselves continuously 
and possess totipotent, pluripotent or multipotent 
ability to differentiate into various cell types (Wis-
let-Gendebien, Laudet, Neirinckx, & Rogister, 
2011). Studies indicate that different lineages of 
SCs promote a series of changes throughout the 
recipient’s CNS not restricted only to the specific 
area (Giusto, Donegá, Cossetti, & Pluchino, 2013; 
Bonnamain, Neveu, & Naveilhan, 2012).
According to Dunnett, Low, Iversen, Stenevi 
and Björkland (1982), implanted animals with 
cholinergically rich cells were able to perform 
a requested task as the control animals; howev-
er, the time required for its execution was much 
higher than that expended by the control animals. 
A cholinergic reinnervation is known to be need-
ed; nevertheless in the study it was insufficient to 
a successful functional recovery (Dunnet et al., 
1982). Some years later, ectopic implantation of 
forebrain ventral cells (cholinergically rich) attenu-
ated learning deficits in rats with cholinergic lesions 
in a study proposed by Barker and Dunnet (1999).
Modo et al. (2002) reported that the privileged 
immune characteristics of CNS can be attributed to 
numerous factors such as the low immunogenetic-
ity of neuronal tissues, the protection of the blood-
brain barrier and the absence of lymphatic drainage 
in the brain. However, CNS immune’s protection 
is only partial once there are differences in species 
between the donor and the host and rejection oc-
curs (Modo et al. 2002). Thus, the treatment with 
immunosuppressive drugs is necessary in cases of 
allogeneic transplants.
MSCs may be defined as progenitor cells ca-
pable of giving rise to a number of unique, differ-
entiated cells from all three germ layers (Caplan, 
1991). First described as fibroblast precursors from 
bone marrow (BM) by Friedenstein, Chailakhjan 
and Lalykina (1970), MSCs may be also referred 
to as a fibroblast colony-forming units or marrow 
stromal cells (Phinney, 2002). Even though these 
SCs have more limited ability of differentiation 
than the embryonic SCs, MSCs have important 
advantages such as the facility for isolation, the ca-
pacity to propagate in culture, besides the non-im-
munogenic characteristics (Bydlowski, Debes, 
Maselli, & Janz, 2009).
Cova et al. (2010) found that human MSCs 
promoted an effective neuronal survival and sup-
ported the development of immature cells in a 
PD’s animal model. According to them, neuronal 
proliferation and maturation were found after the 
implants in animals that had the striatum injured 
by 6-hydroxydopamine (6-OHDA). The same was 
not found in sham animals implanted with the 
same cell line. The results suggest the existence of 
a mutual influence between the grafted cells and 
endogenous neural precursors, becoming important 
to determine the effect on survival neuronal cells 
in other brain regions.
Naive human MSCs consistently synthesize a 
variety of trophic factors that play an important role 
on the improvement observed in implanted animals 
(Cova et al., 2010). However, despite the promising 
outcomes, important issues such as tissue’s viabil-
ity, logistic and ethical concerns surrounding the 
use of human material, cell’s purity and viability, 
deleterious side effects, to site some, need to be 
better evaluated and understood until this practice 
becomes commonly used (Barker, Barrett, Mason, 
& Björklund, 2013).
Bone marrow mesenchymal SCs (BM-MSC) 
show a great potential of proliferating and differ-
entiating into several types of cells, and present 
two major advantages over other cell sources: 
accessibility and immunological features (Olivei-
ra, Haeser, & Pranke, 2008). Besides this, the use 
of BM-MSC’s for grafts circumvents the ethical 
concerns attached to the use of embryonic cells. It 
also brings technical and practical solutions, such 
as simpler cell collection since it has been practiced 
in BM transplants.
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Recent studies show that BM-MSCs are satis-
factory used in intracerebral procedures for neuro-
degenerative diseases in animal models. According 
to Lee, Jin and Bae (2009), BM-MSCs promoted 
microglial activation and reduced significantly the 
Aβ deposit in a mouse model. Hence, BM-MSCs 
can increase the number of activated microglia, 
which supports the hypothesis that BM-MSCs 
might be an effective therapeutic vehicle to reduce 
Aβ deposits in AD patients (Lee et al., 2009).
Adipose-derived MSCs (AMSC) isolated from 
adipose tissue can be differentiated into neuronal 
SCs, and so improve the feasibility for neurodegen-
erative diseases’ treatment. Besides this, AMSCs 
secret anti-apoptotic growth factors, reproducing 
cytoprotective effects in animal models (Im et al., 
2013). Studies have investigated the neuroprotec-
tive effects of the AMSC in animal models of intra-
cerebral hemorrhage and found out evidences of a 
reduction in the acute cerebral inflammation and in 
the chronic brain’s degeneration after implantation, 
which corroborated to improve functional recovery 
(Kim et al., 2007).
Therapeutic potential of intracerebral injection 
of human AMSCs in neurodegenerative diseases 
was previously reported in Huntington’s disease, 
PD and ischemia mouse models, but not in AD 
(Kim et al., 2012). In a carefully designed study 
on therapeutic effects of intravenous human ad-
ipose-derived SCs in an AD model, Kim et al. 
(2012) observed that intravenous or intracerebral 
human AMSC transplantation rescued memory 
impairments, besides reducing the number of Aβ 
plaques in the mice’s brain. There was no notifica-
tion sign of tumorigenisis in this study; nevertheless 
Gimble, Bunnell, Chiu and Guilak (2011) identified 
the formation of sarcomas in vivo after the implan-
tation of AMSCs in immunodeficient mice.
Dental and periodontal tissues constitute a re-
cent source of neural SCs, presenting a substantial 
advantage among other SCs: their neural crest 
phenotype (Ibarretxe et al., 2012). Dental pulp SCs 
(DPSC) and human exfoliated teeth SCs (ETSC) 
have been shown to differentiate into the three germ 
layers, also displaying a potency that was widely 
thought to be exclusive from embryonic SCs (Jane-
bodin et al., 2011; Miura et al., 2003). When com-
pared to BM-MSCs, ETSCs present more active 
and developed metabolic cells (Karaoz, Sağlam, 
Aksoy, Kaymaz, & Duruksu, 2011).
These characteristics were corroborated in a 
study on the differentiation process of human exfo-
liated deciduous teeth SCs into neurons that perfor-
med a dopaminergic function (Wang et al., 2010). 
As a result, it is estimated that the dental pulp SCs 
become an alternative source of human MSCs, on-
ce they offer promising differentiation properties, 
high proliferative capacity, and don’t raise ethical 
concerns as embryonic SCs (Ibarretxe et al., 2012).
Few studies have identified kidney-derived SCs 
(KSCs), especially considering neurodegenerative 
diseases. Studies about the isolation of kidney-de-
rived cells showed consistent characteristics of 
renal SCs, without evidences of cell senescence or 
transformation into malignant tumors (Gupta et al., 
2006). According to Ranghini et al. (2013), studies 
have shown that some kidney stem/progenitor cells 
(KSPCs) can differentiate into a variety of renal 
cell types (Lee et al., 2010).
However, in most cases, differentiation was 
defined solely on the basis of marker analysis, re-
maining unknown whether these stem/progenitor 
cell-derived renal cell types display any functio-
nality. Nevertheless, another study suggested that 
human KSPCs cells improve renal function by 
secreting paracrine factors that promote tubular 
repair (Ranghini et al., 2013; Sallustio et al., 2013).
Conclusions
The development of models for behavior and 
cognitive decline in neurodegenerative diseases is a 
constant challenge for comparative psychology re-
searchers. Associate the search for a comprehensive 
model of a multifactorial condition that may cause 
cognitive impairment is a methodological hotspot. 
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Although it is difficult sometimes to consider a 
model of disease as a useful tool for knowledge 
achievement, models for non-pathological ques-
tions might be even more difficult.
The existing animal models for aging patholo-
gies have been used in the development of various 
treatments and helped to bring discovery for sev-
eral advances in the health sciences. The models 
of cognitive impoverishment such as the lesion 
animal model of Alzheimer’s disease has open 
fields for the study of memory and attention and 
is an important tool for the search of its treatment.
A substantial segment of the aging population 
constitutes the primary risk factor for AD and other 
neurodegenerative disorders. Intensive efforts have 
been dedicated to improve old people’s life style 
habits such as exercise and dietary supplements 
in combination with symptomatic treatment drugs 
to improve age-related cognitive decline and to 
attenuate motor and neurological dysfunction in 
neurodegenerative diseases (Mandel & Youdim, 
2012). However, the adult brain has limited re-
generative capacity and no effective treatment 
options are available (Andresa, Meyerb, Ducraya, 
& Widmera, 2008).
Stem cells-derived therapy constitute promis-
ing prospects for the treatment of CNS disorders, 
once it is known that SCs have a great potential 
to develop into many types and subtypes of cells, 
besides being able of in vitro long-term survival 
and self-renewal (Ibarretxe et al., 2012). Implants 
from SCs demonstrated an improvement in the 
performance of rats in a model for AD in behav-
ioral tests (Bertuzzi et al., n/d). The existence of 
these behavioral improvement is not exclusively 
associated to implants survival. Rehabilitation of 
tissues may occur due to innate mechanisms of 
the SCs to migrate to the lesion site, in particular, 
inflammations, apoptosis or hypoxia, releasing 
trophic factors that accelerate the endogen repair 
(Joyce et al., 2010).
The migration of the SCs to injured tissues in 
animal models is associated to a mechanism not 
yet clearly understood and it is likely involved in 
the production of paracrine, anti-inflammatory 
and anti-apoptotic factors (Roux, Leotot, Cheval-
lier, Bierling, & Rouard, 2011). Paracrine effect is 
defined as a form of communication between two 
different cells. One releases chemical mediators to 
its immediate environment, resulting in a change in 
the behavior of a cell in its adjacent environment 
(Anthony & Shiels, 2013).
Several experiments have demonstrated that 
SCs’ grafts ameliorate a variety of CNS conditions. 
However, crucial issues such as functional connec-
tivity, in vivo differentiation and survival, potential 
for migration to areas of lesion, host’s immune re-
actions or mechanisms regulating these functions, 
are still to be addressed (Oliveira et al., 2008). 
Existing clinical data suggest that transplantation 
is technically feasible and can be carried out safe-
ly. Nevertheless, data on functional outcome and 
long-term efficiency remains preliminary (Andresa 
et al., 2008). A greater understanding of the neuro-
biological and molecular factors that determine the 
progress of the brain disorder will probably lead to 
safer treatments (Oliveira et al., 2008).
Stem cells based therapies represent an emerg-
ing therapeutic approach by which incurable dis-
eases may be treated (Marchetti, Krohne, Fried-
lander, & Friedlander, 2010). This search is deeply 
influenced by the development of new models and 
the comprehension of the relationship between 
behavior, cognition and its biological somatic cor-
respondent.
In neural transplantation, although more should 
be known to clarify all the mechanisms of cellular 
paracrine effects in the host’s tissues, there is a 
good perspective that cell therapies being played 
in the right models might be used to treat neuro-
degenerative diseases.
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